Sanofi News

Sanofi Sarclisa Combo Gains Approval as First-line Multiple Myeloma Treatment

Seeking AlphaSep 20 16:43 ET

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices

BenzingaSep 20 15:26 ET

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC Speakers

Seeking AlphaSep 20 15:00 ET

Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript

Earnings Call TranscriptsSep 20 14:12 ET

Express News | FTC Alleges Pharmacy Benefit Managers Systematically Excluded Cheaper Insulins in Exchange for Expensive, Highly Rebated Alternatives

ReutersSep 20 12:00 ET

Express News | U.S. FTC Sues Units of CVS Health , Cigna , and UnitedHealth for Allegedly Artificially Inflating Insulin Prices

ReutersSep 20 12:00 ET

Express News | FTC Case Does Not Name Insulin Drugmakers Eli Lilly , Novo Nordisk , and Sanofi , but Agency Reserves Right to Sue Later

ReutersSep 20 12:00 ET

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

PR NewswireSep 20 11:08 ET

J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)

TipRanksSep 20 09:05 ET · Ratings

Regeneron, Sanofi Say Eosinophilic Esophagitis Drug Recommended for Children in EU

MT NewswiresSep 20 08:26 ET

Express News | The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending The Expanded Approval Of Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) For Eosinophilic Esophagitis In Children Down To 1...

BenzingaSep 20 07:48 ET

Sanofi's Multiple Sclerosis Drug Slows Disability Progression in Phase 3 Study

Yahoo FinanceSep 20 06:50 ET

Sanofi's (SNY.US) BTK inhibitor Tolebrutinib effectively delays disability progression in MS patients.

At a research conference held by Sanofi in Copenhagen on Friday, late-stage trial data showed that its BTK inhibitor Tolebrutinib can delay disability progression by 31% in patients with non-relapsing secondary progressive multiple sclerosis (MS).

Zhitong FinanceSep 20 06:17 ET

Sanofi Says Tolebrutinib Drug Delayed Progressive MS by 31%

Yahoo FinanceSep 20 05:54 ET

Sanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market Catalysts

TipRanksSep 20 04:46 ET

Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

Zacks Sep 19 14:30 ET

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years

BenzingaSep 18 12:03 ET

Vigil Says FDA Removed Partial Hold on Alzheimer's Candidate

Seeking AlphaSep 17 08:19 ET

Sanofi, AstraZeneca Win US Approval for New RSV Vaccine Manufacturing Line

MT NewswiresSep 16 23:44 ET

Sanofi: Information Concerning the Total Number of Voting Rights and Shares - August 2024

Yahoo FinanceSep 16 12:44 ET